Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-26
2009-08-11
Rao, Manjunath N (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S141100, C424S141100, C424S143100, C435S007100
Reexamination Certificate
active
07572768
ABSTRACT:
Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
REFERENCES:
patent: 4415558 (1983-11-01), Vale et al.
patent: 4489163 (1984-12-01), Rivier et al.
patent: 4533654 (1985-08-01), Lederis et al.
patent: 4594329 (1986-06-01), Vale et al.
patent: 4605642 (1986-08-01), Rivier et al.
patent: 4801612 (1989-01-01), Wei et al.
patent: 4908352 (1990-03-01), Lederis et al.
patent: 5109111 (1992-04-01), Rivier et al.
patent: 5235036 (1993-08-01), Kornreich et al.
patent: 5278146 (1994-01-01), Rivier et al.
patent: 5439885 (1995-08-01), Kornreich et al.
patent: 5493006 (1996-02-01), De Miranda et al.
patent: 5663292 (1997-09-01), Rivier
patent: 5728545 (1998-03-01), Perrin et al.
patent: 5786203 (1998-07-01), Lovenberg et al.
patent: 5824771 (1998-10-01), Rivier
patent: 5844074 (1998-12-01), Rivier
patent: 5869450 (1999-02-01), Wei et al.
patent: 5888811 (1999-03-01), Largent et al.
patent: 6670140 (2003-12-01), Isfort et al.
patent: 6838274 (2005-01-01), Vale et al.
patent: 2338561 (2000-02-01), None
patent: 0 361 954 (1989-09-01), None
patent: 0860501 (1998-08-01), None
patent: WO-88/05663 (1988-08-01), None
patent: WO-95/34651 (1995-12-01), None
patent: WO-96/17934 (1996-06-01), None
patent: WO 96/37223 (1996-11-01), None
patent: WO 97/00063 (1997-01-01), None
Allamand et al. 2000. Human Mol Gen 9:2459-2467.
Collins et al 2003. Int. J. Exp Path. 84:165-172.
Chakkalakal et al. 2005. FASEB J. 19:880-89.
Guyton and Hall, 2006, Textbook of Medical Physiology, pp. 955-956.
Lynch et al 2007. Pharm & Therap 113:461-487.
Daniele et al. 2007. Int. J. Biochem and Cell Biology 39:1608-1624.
Van der Maarel et al 2007. BBA. 1772:186-194.
Kurhara. 2005. Internal Medicine 44:1027-1032.
Capell et al. 2006. Nature Rev Genet. 7:940-52.
Emery. 2002. Lancet. 359:687-695.
Zhang et al 2007. Medical Hypotheses 69:310-321.
Maltzman, OncoLink, www.oncolink.org/custom—tags/print—article.cfm?., downloaded Oct. 6, 2008.
eMedicineHealth, www.emedicinehealth.com/script/main/art.asp?articlekey=58659&pf.
Mancini et al. 1992. Circulation. 85:1364-1373.
Grigoriadis, Dimitri E. et al. “I-Tyrο-Sauvagine: A Novel High Affinity Radioligand for the Pharmacological and Biochemical Study of Human Corticotropin-Releasing Factor2αReceptors.” Molecular Pharmacology 50 (1996):679-686.
Palchaudhuri, M.R. et al. “Isolation and Pharmacological Characterization of Two Functional Splice Variants of Corticotropin-Releasing Factor Type 2 Receptor from Tupaia belangeri.” Journal of Neuroendocrinology 11 (1999):419-428.
Valdenaire, Olivier et al. “A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor.” Biochimica et Biophysica Acta 1352 (1997):129-132.
Perrin, Marilyn H. et al. “Cloning and Functional Expression of a Rat Brain Corticotropin Releasing Factor (CRF) Receptor.” Endocrinology 133.6 (1993):3058-3061.
Reyes, T. M. et al. “Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CFR receptors.” PNAS 98.5 (2001):2843-2848.
Suman-Chauhan, Nirmala et al.“Expression a0nd characterisation of human and rat CRF2αreceptors.” European Journal of Pharmacology 379 (1999):219-227.
Perrin, M. H. et al. S9.7 “Diverse roles of corticotropin releasing factor and their light ligands.” SICB (Jan. 5, 2001) 1168-1169.
Arborelius, L., et al., “The role of corticotropin-releasing factor in depression and anxiety disorders”,Journal of Endocrinology, 1999, 1-12, vol. 160, Society for Endocrinology, Great Britain.
Chalmers, D.T., et al., “Corticotropin-releasing factor receptors: from molecular biology to drug design”,TiPS, Apr. 1996, 166-172, vol. 17, Elsevier Science Ltd., USA.
Chang, C.P., et al., “Identification of a Seven Transmembrane Helix Receptor for Corticotropin-Releasing Factor and Sauvagine in Mammalian Brain,” Neuron 11:1187-1195, 1993.
Chen, R., et al., “Expression Cloning of a Human Corticotropin-Releasing-Factor Receptor,” Proc. National Acad. Sci. USA 90:8967-8971 (1993).
Chrousos, G.P., et al., “Corticotropin Releasing Factor: Basic Studies and Clinical Applications”,Prog. Neuro-Psychopharmacol. &Biol. Psychiat., 1985, 349-359, vol. 9, Pergamon Press Ltd., Great Britain.
Cutler, JR., G.B., M.D., “Corticotropin-Releasing Hormone (CRH): Clinical Studies and Use”,The Endocrinologist, 1997, 10S-16S, vol. 7, No. 1, Suppl. 1, Williams 7 Wilkins.
Dautzenberg, et al., Journal of Neurochemistry, 1997, 69: 1640-1649.
De Souza, E.B, “Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role In Central Nervous System and Immune Disorders”,Psychoneuroendocrinology, 1995, 789-819, vol. 20, No. 8, Elsevier Science Ltd., USA.
Dieterich, K.D., et al., “Corticotropin-releasing factor receptors: An overview”,Exp. Clin. Endocrinol. Diabetes, 1997, 65-82, vol. 105, Johann Ambrosius Barth.
Emeric-Sauval, E., “Corticotropin-Releasing Factor (CRF)—A Review”,Psychoneuroendocrinology, 1985, 277-294, vol. 11, No. 3, Pergamon Journals Ltd., Great Britain.
Gilligan, P.J., et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents”,Journal of Medicinal Chemistry, May 4, 2000, 1641-1660, vol. 43, No. 9, American Chemical Society.
Kishimoto, T., et al., “A Saugvagine/Corticotropi-Releasing Factor Receptor Expressed in Heart and Skeletal Muscle,” Proc. Natl. Acad. Sci. USA, 92:1108-1112, 1995.
McCarthy, J.R., et al., “Recent Advances with the CRF1Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications”,Current Pharmaceutical Design, 1999, 289-315, vol. 5, Bentham Science Publishers B.V.
McCarthy, J.R., et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents”,Annual Reports in Medicinal Chemistry, 11-20, vol. 34, Academic Press.
McDonnell, J., et al., “Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human β2-adrenoceptor,” British Journal of Pharmacology, 1998, 125: 717-726.
Maltin, C.A., et al., “Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients”,Clinical Science, 1993, 651-654, vol. 84.
Martineau, L., et al., “Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men”,Clinical Science, 1992, 615-621, vol. 83.
Medler, S., Comparative Trends in Shortening Velocity and Force Production in Skeletal Muscles, Am. J. Physiol. Regulatory Integrative Comp. Physiol. 283, R368-R378, 2002.
Orth, D.N., “Corticotropin-Releasing Hormone in Humans”,Endocrine Reviews, 1992, 164-191, vol. 13, No. 2, The Endocrine Society, USA.
Owens, M.J., et al., “Physiology and Pharmacology of Corticotropin-releasing Factor”,Pharmacological Reviews, 1991, 425-473, vol. 43, No. 4, The American Society for Pharmacology and Experimental Therapeutics, USA.
Rome, L.R., Clinical Orthopaedics and Related Research, 403S, S59-S76, 2002.
Signorile, J.F., et al., “Increased Muscle Strength in Paralyzed Patients after Spinal Cord Injury: Effe
Isfort Robert Joseph
Sheldon Russell James
Paul Andrew A.
Rao Manjunath N
Shafer Shulamith H
The Procter & Gamble & Company
LandOfFree
Methods for identifying compounds for regulating muscle mass... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying compounds for regulating muscle mass..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying compounds for regulating muscle mass... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115959